Cyclin-dependent kinases (CDKs) are important targets for combating various types of cancer. Inhibitors of the CDK4 enzyme are promising agents for clinical use as anticancer agents. In this study, structure-based and ligand-based drug design methods were applied on a dataset of 52 pyrido[2,3-d]pyrimidin-7-one-based CDK4 inhibitors. Predictive 2D- and 3D-quantitative structure-activity relationship (QSAR) models were developed and were analyzed for understanding the important molecular properties that affect the activity. Molecular docking was conducted to analyze the binding interactions between the ligands and the target enzyme. Also, virtual screening of the ChEMBL database was carried out using the validated QSAR model and the molecular docking procedure. A total of six compounds were identified as potentially novel CDK4 inhibitors that have favorable drug-like properties and can serve as lead compounds for the development of anticancer therapeutic agents.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
